Zenas BioPharma, Inc. (ZBIO) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.71B USD. 52-week range 13.50 to 44.60 USD. Trailing P/E 1.5. Data as of 2026-10-09.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, ...